Leadiant Biosciences Ltd. and Essetifin S.p.A., part of the Leadiant group, were found to have charged unjustifiably high prices for the sale of a medicine used to treat cerebrotendinous xanthomatosis to the National Health System.

The Italian Competition Authority concluded its investigation, confirming compliance with the decision that identified an abuse of dominant position by the two companies.

The companies had exploited their dominant position to charge excessively high prices for the medicine, leading to a significant reduction in price following negotiations with the Italian Medicines Agency (AIFA).

The reduced price, effective from March 15, 2024, represents a substantial decrease from the previous unjustifiably high price and aligns more closely with the price levels before the abusive conduct.